Park Place Capital Corp Has $112,000 Stock Position in Haleon PLC Sponsored ADR (NYSE:HLN)

Park Place Capital Corp lowered its stake in Haleon PLC Sponsored ADR (NYSE:HLN) by 16.5% during the first quarter, HoldingsChannel.com reports. The institutional investor owned 10,869 shares of the company’s stock after selling 2,146 shares during the period. Park Place Capital Corp’s holdings in Haleon were worth $112,000 at the end of the most recent reporting period.

Other hedge funds have also recently added to or reduced their stakes in the company. Opal Wealth Advisors LLC acquired a new stake in Haleon in the first quarter valued at approximately $29,000. FIL Ltd boosted its position in Haleon by 45.7% in the fourth quarter. FIL Ltd now owns 4,049 shares of the company’s stock valued at $39,000 after buying an additional 1,270 shares in the last quarter. Continuum Advisory LLC boosted its position in Haleon by 152.4% in the first quarter. Continuum Advisory LLC now owns 4,753 shares of the company’s stock valued at $49,000 after buying an additional 2,870 shares in the last quarter. Alpine Bank Wealth Management acquired a new stake in Haleon in the first quarter valued at approximately $56,000. Finally, Lindbrook Capital LLC boosted its position in Haleon by 22.6% in the fourth quarter. Lindbrook Capital LLC now owns 9,355 shares of the company’s stock valued at $89,000 after buying an additional 1,724 shares in the last quarter. Institutional investors and hedge funds own 6.67% of the company’s stock.

Analyst Upgrades and Downgrades

A number of analysts have weighed in on HLN shares. HSBC restated a “hold” rating on shares of Haleon in a research report on Wednesday, March 5th. Hsbc Global Res lowered shares of Haleon from a “strong-buy” rating to a “hold” rating in a report on Wednesday, March 5th. Deutsche Bank Aktiengesellschaft reiterated a “hold” rating on shares of Haleon in a report on Monday, March 3rd. BNP Paribas upgraded shares of Haleon to a “strong-buy” rating in a report on Tuesday, May 27th. Finally, BNP Paribas Exane upgraded shares of Haleon from a “neutral” rating to an “outperform” rating and set a $13.40 price target on the stock in a report on Tuesday, May 27th. Five analysts have rated the stock with a hold rating, five have given a buy rating and two have assigned a strong buy rating to the company’s stock. According to MarketBeat, the company currently has an average rating of “Moderate Buy” and an average price target of $12.33.

Haleon Price Performance

HLN stock opened at $10.39 on Friday. The firm has a market cap of $46.70 billion, a price-to-earnings ratio of 26.63, a PEG ratio of 2.97 and a beta of 0.31. The company has a quick ratio of 0.78, a current ratio of 0.98 and a debt-to-equity ratio of 0.53. Haleon PLC Sponsored ADR has a 12-month low of $8.25 and a 12-month high of $11.42. The company’s fifty day simple moving average is $10.72 and its 200 day simple moving average is $10.13.

About Haleon

Haleon plc, together with its subsidiaries, engages in the research, development, manufacture, and sale of various consumer healthcare products in North America, Europe, the Middle East, Africa, Latin America, and the Asia Pacific. The company provides oral health products, such as toothpastes, mouth washes, and denture care products under the Sensodyne, Polident, Parodontax, Biotene brands; and vitamins, minerals, and supplements under Centrum, Emergen-C, Caltrate brands.